View Item 

Show simple item record

Influence of Metoprolol Dosage Release Formulation on the Pharmacokinetic Drug Interaction With Paroxetine
dc.contributor.authorStout, Stephen M.en_US
dc.contributor.authorNielsen, Jaceen_US
dc.contributor.authorWelage, Lynda S.en_US
dc.contributor.authorShea, Michaelen_US
dc.contributor.authorBrook, Roberten_US
dc.contributor.authorKerber, Kevinen_US
dc.contributor.authorBleske, Barry E.en_US
dc.date.accessioned2013-04-08T20:49:29Z
dc.date.available2013-04-08T20:49:29Z
dc.date.issued2011-03en_US
dc.identifier.citationStout, Stephen M.; Nielsen, Jace; Welage, Lynda S.; Shea, Michael; Brook, Robert; Kerber, Kevin; Bleske, Barry E. (2011). "Influence of Metoprolol Dosage Release Formulation on the Pharmacokinetic Drug Interaction With Paroxetine." The Journal of Clinical Pharmacology 51(3). <http://hdl.handle.net/2027.42/97158>en_US
dc.identifier.issn0091-2700en_US
dc.identifier.issn1552-4604en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/97158
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.subject.otherDrug Interactionsen_US
dc.subject.otherCYP2D6en_US
dc.subject.otherCytochrome P‐450en_US
dc.subject.otherPharmacokineticsen_US
dc.subject.otherParoxetineen_US
dc.subject.otherMetoprololen_US
dc.titleInfluence of Metoprolol Dosage Release Formulation on the Pharmacokinetic Drug Interaction With Paroxetineen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Psychiatry, Medical School, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Pharmacy Services, University of Michigan Health System, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Internal Medicine Division of Cardiology, Medical School, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumUniversity of Michigan College of Pharmacy, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherAnn Arbor Pharmacometrics Group, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherLexi‐Comp, Inc, Hudson, Ohioen_US
dc.identifier.pmid20400652en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/97158/1/0091270010365559.pdf
dc.identifier.doi10.1177/0091270010365559en_US
dc.identifier.sourceThe Journal of Clinical Pharmacologyen_US
dc.identifier.citedreferenceOtton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther. 1988; 247: 242 – 247.en_US
dc.identifier.citedreferenceBoucher M, Duchêne‐Marullaz P, Moundanga JL. Studies on the stereoisomers of beta‐adrenoceptor antagonists in conscious A‐V blocked dogs. Br J Pharmacol. 1986; 89: 119 – 127.en_US
dc.identifier.citedreferenceWahlund G, Nerme V, Abramsson T, Sjöquist PO. The beta 1‐and beta 2‐adrenoceptor affinity and beta 1‐blocking potency of S‐ and R‐metoprolol. Br J Pharmacol. 1990; 99: 592 – 596.en_US
dc.identifier.citedreferenceBorg KO, Carlsson E, Hoffmann KJ, Jönsson TE, Thorin H, Wallin B. Metabolism of metoprolol‐(3‐h) in man, the dog, and the rat. Acta Pharmacol Toxicol (Copenh). 1975; 35 ( suppl 5 ): 125 – 135.en_US
dc.identifier.citedreferenceOnalan O, Cumurcu B, Bekar L. Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine. Mayo Clin Proc. 2008; 83: 595 – 599.en_US
dc.identifier.citedreferenceKarim A, Piergies A. Verapimil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. Clin Pharmacol Ther. 1995; 58: 174 – 184.en_US
dc.identifier.citedreferenceBleske BE, Welage LS, Touchette MA, Edwards DJ, Rodman DP, Shea MJ. Evaluation of dosage‐release formulations on inhibition of drug clearance: effect of sustained‐ and immediate‐release verapamil on propranolol pharmaocokinetic parameters. Ther Drug Monit. 1994; 16: 216 – 220.en_US
dc.identifier.citedreferenceBleske BE, Welage LS, Rose S, Amidon GL, Shea MJ. The effect of dosage release formulations on the pharmacokinetics of propranolol stereoisomers in humans. J Clin Pharmacol. 1995; 35: 374 – 378.en_US
dc.identifier.citedreferenceGoryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol. 2008; 64: 275 – 282.en_US
dc.identifier.citedreferenceHemeryck A, Lefebvre RA, De Vriendt C, Belpaire FM. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther. 2000; 67: 283 – 291.en_US
dc.identifier.citedreferenceLennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolizers. Clin Pharmacol Ther. 1983; 34: 732 – 737.en_US
dc.identifier.citedreferenceJonkers RE, Koopmans RP, Portier EJ, van Boxtel CJ. Debrisoquine phenotype and the pharmacokinetics and beta‐2 receptor pharmacodynamics of metoprolol and its enantiomers. J Pharmacol Exp Ther. 1991; 256: 959 – 966.en_US
dc.identifier.citedreferenceDayer P, Leemann T, Marmy A, Rosenthaler J. Interindividual variation of beta‐adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol. Eur J Clin Pharmacol. 1985; 28: 149 – 153.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
0091270010365559.pdf
Size:
391.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.